Lai Lai is indeed in deep negotiations to acquire Verve, with a transaction amount not exceeding 1.3 billion dollars.

The Financial Times reported, citing two unnamed sources, that Gilead will pay nearly $1 billion to acquire Verve, and an additional $300 million after the biotech company reaches certain clinical milestones. Gilead declined to comment on the report. Verve has not yet responded to requests for comment. The deal could be announced as early as this week.